Hemophilia B

Return to The Medical Biochemistry Page

DMCA.com Protection Status
© 1996–2017 themedicalbiochemistrypage.org, LLC | info @ themedicalbiochemistrypage.org

Introduction to Hemophilia B

Hemophilia B, also known as factor IX deficiency or Christmas disease, is an X-linked recessive bleeding disorder caused by defects in the vitamin K-dependent enzyme factor IX of the clotting cascade. Factor IX is also known as the Christmas factor, hence the association of hemophilia B with the term Christmas disease. Activated Factor IX (factor IXa) is the enzyme responsible for the activation of factor X to Xa in a reaction referred to as the "tenase" complex. A cofactor in this reaction is factor VIII, deficiencies in which result in hemophilia A. The factor IX gene (symbol: F9) resides on chromosome Xq27.1-q27.2 and is composed of 8 exons that encode a 461 amino acid preproprotein. The F9 gene resides near the fragile X locus. The gene spans 34 kilobases (kb) and is composed of 8 exons. Multiple mutations have been identified leading to hemophilia B. A complete compilation of all of the mutations can be found at the hemophilia B database. Hemophilia B results in a bleeding disorder that is clinically indistinguishable from the more common hemophilia A. Hemophilia B occurs in approximately 1 in 30,000 male births.

Clinical Features of Hemophilia B

The major symptom of hemophilia B is spontaneous bleeding into the joints and the soft tissues of the body. The disease exhibits three levels of manifestation. The severe disease results in patients with <1% of normal factor IX protein in the circulation, moderate disease results from 1%–5% of normal factor IX protein and mild disease is found when patients have 6%–30% of normal factor IX. The most common clinical symptom of hemophilia B that requires therapeutic intervention is soft tissue hemorrhage and hemarthroses (bleeding in the joints). The leading cause of morbidity and mortality in hemophilia B patients is intracranial hemorrhage. Severely affected patients are usually diagnosed before age 1. The most effective treatment for hemophilia B patients is the administration of highly purified factor IX concentrates or recombinant factor IX.












return to Blood Coagulation page
back to the Inborn Errors page
Return to The Medical Biochemistry Page
Michael W King, PhD | © 1996–2017 themedicalbiochemistrypage.org, LLC | info @ themedicalbiochemistrypage.org

Last modified: April 4, 2017